Journal Article

Hyperkalaemia in the age of aldosterone antagonism

A. Chapagain and N. Ashman

in QJM: An International Journal of Medicine

Published on behalf of Association of Physicians of Great Britain and Ireland

Volume 105, issue 11, pages 1049-1057
Published in print November 2012 | ISSN: 1460-2725
Published online June 2012 | e-ISSN: 1460-2393 | DOI: http://dx.doi.org/10.1093/qjmed/hcs106
Hyperkalaemia in the age of aldosterone antagonism

Show Summary Details

Preview

Hyperkalaemia is well recognized as a medical emergency. However, with the publication of trials showing benefit with renin-aldosterone axis suppression in heart failure, the epidemiology of patients presenting with hyperkalaemia has changed. The reported incidence of rate of serious hyperkalaemia (>6.0 mEq/l of potassium) ranges from 6 to 12% in patients on spironolactone with congestive cardiac failure (CCF). A rational choice of therapy based on present evidence is different from the traditionally used algorithm, given our understanding of the physiology relevant to this patient group. This article discusses the changing face of hyperkalaemia and the present evidence and discusses options in treatment of hyperkalaemia.

Journal Article.  4471 words.  Illustrated.

Subjects: Medicine and Health

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.